

Intro to ePRO – Part I

J. Jason Lundy, PhD – Critical Path Institute

Valdo Arnera, MD – PHT Corporation

December 17, 2014





- Overview of the ePRO Consortium and modes of administration (~20min)
- Discuss trends with collecting clinical data electronically (~20min)
- Q&A (~15min)

Critical Path Institute (C-Path)



- Established in 2005 by the University of Arizona and the FDA's Center for Drug Evaluation and Research (CDER)
- Dedicated to implementing FDA's Critical Path Initiative - a strategy for transforming the way FDA-regulated products are developed, evaluated, manufactured, and used
- An independent, non-profit organization
- Provides a neutral, pre-competitive venue for collaboration aimed at accelerated development of safe and effective medical products

ePRO Consortium



The Critical Path Institute established the ePRO Consortium on April 1, 2011

Mission: To advance the quality, practicality, and acceptability of electronic data capture (EDC) methods used in clinical trials for PRO endpoint assessment





Benefits of Collaboration



A coordinated approach to gathering evidence supporting the measurement equivalence of the various ePRO modes

Collective development of ePRO migration best practices

- Methodological guidance on ePRO implementation in clinical trials (e.g., mixing modes within a trial)
- Development of publicly available specification documents for migrating specific PRO instruments to available ePRO platforms

PRO Consortium



Formed in late 2008 by C-Path, in cooperation with the FDA's CDER and the pharma industry

- Membership
 - 27 members (pharmaceutical firms) in 2014
- Non-Voting Participants
 - Representatives of governmental agencies (FDA, EMA, NIH)
 - Clinical consultants, academic researchers, patients, and CROs partnering in the development and testing of PRO instruments

PRO Consortium: Goals



- Develop <u>qualified</u>, publicly available PRO instruments for use in the assessment of primary or secondary clinical trial endpoints
- Enable pre-competitive collaboration that includes FDA input and expertise
- Avoid development of multiple PRO instruments for the same purpose
- Share costs of developing new PRO instruments
- Facilitate FDA's review of medical products by standardizing PRO endpoints

PRO Consortium Working Groups



Objective: To produce and/or compile the necessary evidence to enable new or existing PRO instruments to be qualified by the FDA for use in clinical trials where PRO endpoints can be used to support product labeling claims.

- Asthma
- Cognition
- Depression
- Functional Dyspepsia
- Irritable Bowel Syndrome
- Rheumatoid Arthritis
- Non-Small Cell Lung Cancer

Clinical Outcome Assessment (COA)



Clinical outcome assessment (COAs)

- Patient-reported outcome assessments (PROs)
- Clinician-reported outcome assessments (ClinROs)
- Observer-reported outcome assessments (ObsROs)
- Performance outcome assessments (PerfOs)

A patient-reported outcome (PRO) is any report of the status of a patient's health condition that comes directly from the patient, without interpretation of the patient's response by a clinician or anyone else.

A PRO instrument is used to measure *treatment benefit* or risk in medical product clinical trials.

The Problem with Patient Satisfaction



Not part of FDA regulatory authority 21 CFR 314.126—"purpose of conducting clinical investigations of a drug is to distinguish between the effect of a drug from other influences..."

Pharma cares a lot—FDA sees no implication for labeling, particularly when the goal is comparative The Problem with Health-Related Quality-of-Life (HRQoL)



<u>Might</u> reflect treatment benefit, but not useful in the absence of a measure of core symptoms

- Problems in generating labeling claims
 - Logically distal outcomes
 - Unclear expectations about change across duration of trial

Often risky strategy, better left to exploratory outcomes

Modes of Administration



- Paper
 - Digital Pen
- Screen-based use an app or web interface
 - Handheld
 - Tablet
 - Desktop and Laptop Computers

Telephone-based

Interactive Voice Response (IVR)

Improvements in Data Collection



Advantages of ePRO instruments over paper-based instruments

- contain the paper tornado
- avoid manual data entry and database creation
- more accurate and complete data
- Benefits that do not exist on paper
 - seamless skip logic, real-time edit checks, calculations, and alarms

May increase participation of subjects from typically underrepresented groups, such as those of lower income or lower literacy

Benefits of Electronic Data Capture



Allows the potential for event-driven data collection

- Concatenated items
- Complex items
- Adaptive design
 - Immediate data availability for decisions
 - Monitor compliance

Enables real time compliance monitoring Permits PRO data integration to eCRF

Recent ePRO-based Labeling Claims



Jakafi® - Incyte Corporation (2011)

 Myelofibrosis Symptom Assessment Form (MFSAF) v2.0 handheld diary

Secondary endpoint – comparison of proportion of subjects with a 50% or greater reduction in total symptom score

- Subsys® insys Therapeutics, Inc. (2012)
 - Visual Analogue Scale handheld diary

Primary endpoint – mean sum of pain intensity differences at 30 minutes (after administration)

Linzess[™] - Ironwood Pharmaceuticals & Forest Laboratories (2012)

 11-point NRS of Abdominal Pain at its Worst - IVRS
Co-primary endpoint – along with Complete Spontaneous Bowel Movements

Is there a downside to ePRO?



Disadvantages of ePRO instruments over paper-based instruments:

- High technical and training burden on site and/or monitoring staff
- Management of eSource rather than more familiar paper source
- Data integration may occur outside of the clinical data system
- Unable to offer a paper back-up when employing skip logic, adaptive algorithms, etc.

May selectively decrease participation by subjects from unidentified subsets

Considerations for ePRO Migrations



Infrastructure for electronic data collection

Cellular signals, internet connectivity

Language and translations

- Assume that translated text will take more space (i.e., more characters) than US English
- Certain formatting does not translate well (e.g., fonts, capitalization, and underlining)

Benefits that do not exist on paper

 seamless skip logic, real-time edit checks, calculations, and alarms

But wait, there's a catch



"When a PRO instrument is modified, sponsors generally should provide evidence to confirm the new instrument's adequacy."

• From the FDA's PRO Guidance (FDA 2009)

Section F. Instrument Modification, pages 20-21

"Examples of changes that can alter the way that patients respond to the same set of questions include:

- Changing an instrument from paper to electronic format
- Changing the order of items, item wording, response options, or recall period or deleting portions of the questionnaire
- Changing the instructions or the placement of instructions within the PRO instrument"

Items of Concern on Paper



Please complete either 6 or 7 (not both)

6. Decreased Appetite:

- 0 There is no change in my usual appetite.
- 1 I eat somewhat less often or lesser amounts of food than usual.
- 2 I eat much less than usual and only with personal effort.

3 I rarely eat within a 24-hour period, and only with extreme personal effort or when others persuade me to eat.

- OR -

- 7. Increased Appetite:
 - 0 There is no change in my usual appetite.
 - 1 I feel a need to eat more frequently than usual.
 - 2 I regularly eat more often and/or greater amounts of food than usual.
 - 3 I feel driven to overeat both at mealtime and between meals.

Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P.T., Kornstein, S., Manber, R., Thase, M. E., Kocsis, J. H., and Keller, M. B. (2003). The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), Clinician Rating (QIDS-C), and Self-Report (QIDS-SR): A Psychometric Evaluation in Patients with Chronic Major Depression. <u>Biological Psychiatry, 54:573-583.</u>

Types of testing for ePRO adaptation



Conceptual equivalence

 Do the subjects understand and interpret the modified instrument the same as the original paper-based instrument?

Statistical equivalence

• Are the scores obtained from the modified instrument the same as those from the original?

Coons SJ, Gwaltney CJ, Hays RD, et al (2009). Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force Report. *Value Health* 12(4):419-429.

Equivalence Testing



Qualitatively assess conceptual equivalence

- Small scale (n=15) cognitive interviewing to ensure understanding and ePRO usability
- The paper and electronic questionnaire may be completed by the subject, and the variation in response explored with the subject
- Not aimed at assessing the content of the original measure

Poor paper measure = Poor electronic measure

Equivalence Testing



Quantitatively assess whether the data produced among alternative modes of administration are equivalent

- Larger scale (n=60-120), repeated-measure design Crossover design, comparing paper and electronic Assess score agreement (e.g., mean differences, ICC)
- Only necessary when moderate levels of change have been made during the migration
- Assumes the validity of the measure remains intact

Problems with Equivalence Testing



Authors may have varying opinions on demonstrating agreement

Paper is an imperfect "gold standard"

- Poor paper measure = Poor electronic measure
- Some items may have content validity, but perform poorly or have a lot of statistical noise

ePRO Recommendations



- Use ePRO with the understanding that there will be circumstances where it may not be appropriate
- Keep subject burden in mind/streamline user interface
- Expectations must be set with sites & patients
- Quality documentation must complement ePRO
- Adequate training will lower resistance & anxiety for new users
- Monitor compliance actively & educate sites about associated responsibilities
- If the Sponsor team is new to ePRO, appropriate training will ensure all understand the process and associated expectations
- Apply the same rigor to ePRO that is applied to PRO



Where are we with Patient-Driven eData?

Valdo Arnera, MD – PHT Corporation

Patient eData Annual Adoption 2002-2013





New trial starts

4,000 → 5,250*

% of studies that Collect PRO Data

15% → 35%*

% of studies that use ePRO

Number of ePRO Trials

5% → 45%*


 $30 \rightarrow ?$

* PHT Corporation Estimates

Patient eData Annual Adoption Rate - 2011




ePRO Platforms




Number of Patient eData Trials 2002-2013





Number of Patient eData Trials 2002-2025 ?





Increased Quality / Mode of Collection




- Insomnia
- Chronic Constipation
- Urinary Incontinence
- Asthma

The increased quality is very similar across TAs


Merck Insomnia Study



- One of the first randomized studies comparing eDiaries and paper on their relative capacity to show efficacy
- Two arms underwent an approved treatment for Insomnia
- Study performed by Merck Research Laboratories



Paper and eDiary Data: Δ Sleep Time



©PRO CONSORTIUM CRITICAL PATH INSTITUTE

Summary of Results



Area of Interest in Trial	PHT LogPad	Paper Diaries
Calculated patients to yield 90% study power	N=44	N=101 (56% more than LogPad)
Potential cost savings	\$340,000 *	
Distribution of responses	More Gaussian	Suggests recall bias
Standard deviation	35% smaller	
Sleep Change estimates	Nearly identical	
Coefficient of variance	Significantly smaller	
Data Point Changes and Notification Forms		3x more of each
Compliance (% of diaries completed)	92% objective subject compliance	96% purported subject compliance
Cost: Data Entry (hr)	0	58
Data Review (hr)	10.5	10.5

* Estimated by assuming a total per-patient cost of \$6,000

Results presented at DIA 2004 and at the International Society for Quality of Life Research (ISOQOL) 2004 symposium

Tegaserod in Chronic Constipation



Tegaserod relieves multiple chronic constipation symptoms in men

Fried M,¹ Johanson JF,² Gwee KA,⁸ McDowell B,⁴ Pecher E,⁴ Shetzline M⁴ University Hospital Zürich, Gestraenterology and Hepetalogy, Zürich, Switzonand, 'Bockford Gastraontorology Ass Gastroenterology, Rocklord, USA: "Gleneagles Hospital, Gastroenterology, Singapore, Singapore, Novarts Pharma AG Basel, Switzerland: "Novartis Pharmaceuticals Corporation, East Hanover, USA

C. Martin Martin Martin

Caral Market

 Material Constraints of the standard strength
 Strengt
 Strength
 Strength</t

Bigel trendy on an explaint of stational pulletter water terms that a closer or A monitorease and a CoBMM suck in which of a patiently Microsov (Spring constants) of the plant of the such as in a CoBM on a SuCM, respectively, and constants of the plant of the such as in a CoBM on a SuCM, respectively, and Bran water during to fair worden 1, 12 years start titlen foart (12.000 in gewond) werene (11.15) wiekenig op -0.0550 (Figure 2)

anome (1): Styletokog (2005) (2) (2) (2): Styletokog (2): S

CONTRACTOR OF STREET, STREET,

، ~~~ يه الس

Tor all the Problem bases 2 4 -

Obange in bowel frequency

Start Start start

Land Land Mark

RESULTS (cont'd)

Sector 100 1 A.D.

and they prove a start

BACKGROUND

 Charak sensity den Kitalisis sommer garanteret si Gårprener sterring 2 385 alle Skitalis i Vestern som ref. 2. Bits all statuted in Vision countries: Transition to weak against a connection countries at target neg on y of a pairs with the full opposition a mean pairs of a set of a larget countries and a mean address of the set of a set of a larget of system means in U.C. Bits industry and pairs of a set of a larget country of a set of set of the set of the set of the set of the system means in U.C. Bits industry and a set of the set of the set of set of the set When the valid characteristic matching is the structure product way with the structure of the structure of

OB JECTIVE

To non-new the observation which of the same of Hung Is all phonon in male politicial and CL

METHODS

Study design - temierowani, naturel 4 dan casta cant al ut mail batter tital of interfloady and ensure or temperature (cast is a 2). Telephone is a series of the first style as in the "Association and the series" (Association and the series of the series).

Patient recruitment 1 Mai 18 years et daar situsi saaya' eerdipalen ferstigast "interfer Managemente Construction with distinction without state quartization showed in new contra COBM (New July 2, 5, 202 of mine of the initiality symmetry and institution of nt ante: say all diordechard zoolo (jose i anter Plan ine l'heini dra Noble' sanation of neuropole even aller see filty

Efficacy ondpo

Assessment of the superfinite of upplicity, since terms straining and the region operations are allocated and upplicity solution to the terms of the second mean mean state. If an extension of particle provides and of the bond mean mean state. If an extension of particle provides and of the second Primery anapproxit mapped prior (2016) for any sense 1-4, where non-maintened of these primers was an invested a more framework of all 122000 to be accepted with benefits. $d_{\rm eff}$ (w.2.5.1.12 \pm members of the obstantial value of the probability of the pr Salety assessments ente pilo, entre estado Asia (SReal estas comunal Sando e abreate o-cluttons of a new and physical sections, and was

Statistical analysis represented have a sub-weak analyzed using a leader representation for which the -h - <1 CD (table is base in , used of as an and the interpret induced in the most h

P where symmetry means the map for marking. Addition with start

RESULTS

Patient recruitment and baseline domographilds Nexteenses in daily-adjust ration as is represented to the current recipient Statistications consistent present is one if



1 A LET THE CALL OF THE CALL O The second secon

To execut age of the regioner developments of a contrast of the axes of a large strength of the second strength of (a) the the interview of the second secon 3. dig 21: 14 cay applies period, the measures have a ballwhild was \$2000 2.4 to exclusion and an applies the transmission are period. Take 3. Figure 4. The dynamics mining associate to size of 64 MeVA (MeVA) and a branch free boother of a 1552 MeVA provide a social 1.17 for basis > 0.

RESULTS (cont'd) Teacees deviced pair is had a partie to man earlier of BRAW will don't avera 1-17 compared with also be acted patents (Teals 2). -spectral way as constantly the case of neuron access that, because a <1 -behavior of the spectra α -spectra β -spectra β

Pail ends intraces with regestered experienced their than process. Intraces patients (decar of chant)

feet on stool consistency and straining Toppsend was dyn feartly solar ar top asshollt softwritte vian GRM far 17 oct of 12 writin (ast 67) Rei ev fil Archistra al strategic data from SRRS democratical Har legatores was given ally one class 2 of a prant improvement of the legatores of the provide your class 2 of a prant improvement of the your 3 - 12 for maximum class and ally prant and a frame (in Archistra 2) for 3 and 12 years may a strategic all depression with the maximum class and all prant of a pro-met your legatores and ally prant of the depression of the prant many strategic all depression for the maximum class and all prant many strategic all depression of the theory and the strategic allocation of the strategic allocation of the strategic allocation of the strategic strategic allocation of the strategi

أشرب المسمو المحالم s an Equate Social Spiritizes with a start

L. market Mark P. S. Mark P. S. Mark P. Mark

Togesence adalitient was associated with a present communities in Intro globs coarse nation relief score for it out with? vareane upper statutes the difference being significant graft ("The Similar IV waves terpreses vegetiese (E, c.d. co. dis both stampings of somelige) on programming the sense rescale on agricult of 12 within

Perform to the other prevent in the table galaxy second and shall shall be in the form of the prevent second and states the second seco

6 miles propertines en recto Auto tratti programma i anal d'Albatt, para 87.355, plantes 32.357, volte lle nova nor numero d'Albatt, 24.857, accentrationes 300 anti protonomi (24.24) ultan din adam dar te Alb anne bit sport a talla hadana dig aga Jaga zanz 4.456 plastor - 250 House, activity accessed decontract of any converse approximation of the solution to call a process of a contract of the solution to call a call a local decision.

environment of the second state of the seco

contract in the sport of the parameter is a visco parameter in 2010 DOD State (1990) State (1997) in the state of the second state of the State (1990) and (1990) in the state of the state The ensure as easis of a in cally significant formation more an easi as a we form the case of indexts was reported in the tegestern scenario

CONCLUSIONS CONCLUSIONS In a coub to 20 High to be not ask the entry of stanky of the analysis of the intervence of the CON-Styrithm the view levels will be a standard of CONTENT in a standard window will be a standard a standard of CONTENT in the first entry of the standard of the CONTENT into the standard standard of the Standard s (cause of was well colorated in men with C7 -

REFERENCES Marthurst, and "A" second lines and the second seco


The second case basised by Here ($p \in p_1 \otimes p_2 \in P_2 \otimes p_2 \otimes p_3 \otimes p_4 \otimes p_4$

Poster presented at WCOG 2005

Protocol had planned 1026 patients Study was interrupted **Drug Efficacy was** shown with 322 randomized patients


Differences in Std Deviation: Primary Efficacy Endpoint (CSBM)





Differences in Std Deviation: Primary Efficacy Endpoint (Micturitions)





S. McKenzie et al, "Proving the eDiary dividend", Applied Clinical Trials, Jun 2004

Increased Quality / Privacy



A 4 weeks randomized cross-over trial to compare 2 methods of data collection (electronic and paper) in subjects with FSD Female Sexual Encounter Profile (adapted)© Ferguson 2002

Inclusion Criteria


- Females with symptoms of sexual dysfunction
- In a stable, hetero-sexual relationship
- Minimum age of 18 yrs

Study included 27 Patients

One doesn't speak to paper the same way than to a PDA

Increased Quality / Privacy






Female Sexual Encounter Profile Completion

Increased Quality / Cheating Prevention



Use of an electronic Peak Flow meter to assess compliance vs. paper diaries filled in by the patient.




Objective measurements of compliance in asthma treatment. F. Chmelik et al, Annals of Allergy, Dec 1994

Increased Quality / Cheating Prevention



Blood Glucose Values recorded in the Glucometer and on the Paper diary



Reliability of Blood Glucose Monitoring by Patients with Diabetes Mellitus R.S. Mazze et al, The American Journal of Medicine, Aug 1984

Differences in SD: Efficacy Endpoint = PEF



New trial including 2300 patients, 6 months treatment Approximately 90% paper diaries / 10% eDiaries

Aim: to investigate if the results differed between paper and eDiaries

Residual		Morning PEF (L/min)
Standard	pDiary	44.1
deviation	eDiary	38.3

Use of an eDiary can decrease the variability in mPEF Tendency of lower standard deviations in majority of eDiary endpoints Indicate increase in the quality of the data Increased precision fewer patients needed


Integration of Objective Measurement Devices & ePRO






Combines objective and subjective data enriches voice of patient





Flushes at the menopause







Urinary Incontinence



Timed assessments in various pain models








Ease of collection has no age






Age has little / no affect on average compliance of diary completions


Ease of collection has no borders





Ease of collection does not seem to stop





CONCLUSIONS: This analysis of the study meta-data is further proof that subjects can, and are willing, to complete daily diaries electronically. This is regardless of their age or country of origin. Additionally, the duration of participation in the trial is not a burden that has significantly impacted their ability to complete their diaries.

Shortened Recruitment / Decreased Drop-out



Study based on events rather than patients (COPD exacerbations, Migraine attacks, Bleedings in Hemophilia, Restless Legs Syndrome,...)

- need for 500 events
- based on events' occurrence in previous studies (paper diaries)
- planned recruitment of 14 months

Study Results

- 2 to 3 times more events than expected
- only 1 withdrawal of consent when much more was anticipated
- study ended 8 months earlier (recruitment of 6 months instead of 14)

Patients were asked why: The answer was that they behaved differently because of ease of use

New FDA Draft Guidance (1)



Guidance for Industry Irritable Bowel Syndrome — Clinical Evaluation of Drugs for Treatment

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)

> May 2012 Clinical/Medical

New FDA Draft Guidance (2)



4. Efficacy Measures

Sponsors should choose a format for daily sign or symptom assessment (e.g., interactive voice response or personal digital assistant) so that patients can evaluate their IBS signs or symptoms on a daily basis throughout the trial. When assessing responses, sponsors should consider two distinct approaches: (1) examining the difference in average score (or average change from baseline score) between the treated and untreated groups; or (2) examining the difference in response rate in the treated and untreated groups, where the response is prospectively defined and represents an effect considered clinically meaningful. In many instances, an effective drug will have an effect on both measures.



Q&A